Publication | Open Access

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

VaccinationVaccine SafetyVaccinologySafety AnalysesHuman Papillomavirus VaccinesFinal EfficacyDouble-blind TrialGynecologyVaccine TestingVaccine EfficacyVaccine HesitancyMedicineEpidemiologyWomen's Health